The global tele-epilepsy market was valued at USD 0.37 billion in 2021 and it is predicted to surpass around USD 1.2 billion by 2030 with a CAGR of 13.97% from 2022 to 2030.
Report Highlights
The COVID-19 pandemic had a positive impact on the tele-epilepsy industry. The outbreak severely impacted the healthcare system and the economy, which created a special barrier for individuals seeking medical care, including epilepsy care. In addition, telehealth initiatives have demonstrated a high level of patient and physician satisfaction and quality during COVID-19. It has been seen that providing complex epilepsy care, including to patients with severity in epilepsy, could be solved, and can produce results that are comparable to those of in-person consultations.
Governments worldwide are initiating programs to uplift the market for tele-epilepsy. For instance, several government entities are embracing telehealth by implementing new regulations and reimbursement standards. In March 2020, The Federal Communications Commission in the US developed initiatives to aid healthcare organizations in implementing telemedicine technology.
Scope of The Report
| Report Coverage | Details |
| Market Size in 2021 | USD 0.37 billion |
| Revenue Forecast by 2030 | USD 1.2 billion |
| Growth rate from 2022 to 2030 | CAGR of 13.97% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segmentation | Patient, component, end-use, region |
| Companies Covered |
Shimmer; Empatica; SOC Telemed; Eagle Telemedicine; Sevaro; Tele Specialists; Chiron Health; RTTC; Science Soft USA Corporation; Vidyo, Inc. |
Patient Market Insights
The adult patient segment held the largest market share of 57.2% in 2021, as a result of an increase in the adult population considering the severity. An adult suffering from epilepsy is at more risk of getting into severe conditions after seizures, which increases the role of tele-epilepsy. Based on patients, the tele-epilepsy market is segmented into pediatric and adult segments.
The pediatric segment is anticipated to expand at a CAGR of 15.63% during the forecast period. Epilepsy cases in children are different from those in adults, in the context of seizure type and epilepsy syndrome, as children have higher immunity levels and are less prone to other diseases. For instance, juvenile convulsions and epileptic syndromes like Lennox-Gastaut disorder, childhood absence epilepsy, and Dravet syndrome are frequently distinct in the pediatric population.
Component Insights
The hardware component held the largest share of over 41.02% in 2021, due to the extensive use of videoconferencing technology, audio equipment, microphones, and other medical accessories to support virtual visits. For instance, in March 2021, IVP Research Labs, Schlesinger Group, and Shimmer Research launched the official NeuroLynQ service process for central location studies. It offers a remote biometric tracking device that makes it possible to assess users' unconscious human emotions while they are home. Based on component, the market is segmented into hardware, service, and software.
The service segment is anticipated to progress at a CAGR of 16.43% during the forecast period from 2022 to 2030, owing to the growth of remote patient monitoring solutions. The segment growth will be fueled by the widespread usage of teleconsulting between patients and clinicians. For instance, in September 2019, Eagle Telemedicine announced the launch of TeleNocturnist and TeleHospitalist programs at the Jersey Community Hospital. This initiative will help expand the reach of the company’s services across rural locations in the U.S.
End-use Insights
The hospital segment accounted for a substantial revenue share of 34.23% in the market in 2021 and is expected to expand at a healthy CAGR of 15.76% during the forecast period. The growth is anticipated as hospitals are preferred by patients for their treatment process, in the context of convenience and variety of product offerings in one place. Moreover, hospitals are omnipresent and easily accessible to all patients. Based on end-use, the market is segmented into hospitals, payers, and healthcare consumers.
The healthcare consumer segment is poised to witness growth in the adoption of teleconsultation services because of the efficiency and effectiveness of online consultation, with the benefit of getting treatment in time of emergency from their place.
Regional Insights
North America dominated the market with a revenue share of 37.91% in 2021, owing to the technologically advanced infrastructure, rising number of epilepsy cases, and growing per capita income. In addition, presence of many market players and supporting government regulations in the region are boosting regional growth. For instance, in March 2020, The Federal Communications Commission in the U.S. developed initiatives to aid healthcare organizations in implementing telemedicine technology.
Asia Pacific is expected to expand at a CAGR of 16.77% during the assessment period, owing to the significant adoption of advanced technologies, enhanced network connectivity, rising incidence of epilepsy cases, and increased government program offerings.
For instance, in February 2022, the Myanmar WHO Program launched for Reducing the Epilepsy Treating Gap and the Psychiatric Gap Action Program succeeded in achieving these objectives. These initiatives aimed to improve the capacity of community-based primary care and non-specialist healthcare practitioners to identify, manage, and follow up on epilepsy patients. Due to the impact of these 4 pilot programs, 6.5 million people have received epilepsy treatment.
Key Players
Market Segmentation
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Tele-Epilepsy Market
5.1. COVID-19 Landscape: Tele-Epilepsy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Tele-Epilepsy Market, By Patient
8.1. Tele-Epilepsy Market, by Patient, 2022-2030
8.1.1 Pediatric
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Adult
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Tele-Epilepsy Market, By Component
9.1. Tele-Epilepsy Market, by Component, 2022-2030
9.1.1. Software
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Hardware
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Service
9.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Tele-Epilepsy Market, By End-use
10.1. Tele-Epilepsy Market, by End-use, 2022-2030
10.1.1. Hospitals providers
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Payers
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Healthcare consumers
10.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Tele-Epilepsy Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Patient (2017-2030)
11.1.2. Market Revenue and Forecast, by Component (2017-2030)
11.1.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Patient (2017-2030)
11.1.4.2. Market Revenue and Forecast, by Component (2017-2030)
11.1.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Patient (2017-2030)
11.1.5.2. Market Revenue and Forecast, by Component (2017-2030)
11.1.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Patient (2017-2030)
11.2.2. Market Revenue and Forecast, by Component (2017-2030)
11.2.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Patient (2017-2030)
11.2.4.2. Market Revenue and Forecast, by Component (2017-2030)
11.2.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Patient (2017-2030)
11.2.5.2. Market Revenue and Forecast, by Component (2017-2030)
11.2.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Patient (2017-2030)
11.2.6.2. Market Revenue and Forecast, by Component (2017-2030)
11.2.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Patient (2017-2030)
11.2.7.2. Market Revenue and Forecast, by Component (2017-2030)
11.2.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Patient (2017-2030)
11.3.2. Market Revenue and Forecast, by Component (2017-2030)
11.3.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Patient (2017-2030)
11.3.4.2. Market Revenue and Forecast, by Component (2017-2030)
11.3.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Patient (2017-2030)
11.3.5.2. Market Revenue and Forecast, by Component (2017-2030)
11.3.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Patient (2017-2030)
11.3.6.2. Market Revenue and Forecast, by Component (2017-2030)
11.3.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Patient (2017-2030)
11.3.7.2. Market Revenue and Forecast, by Component (2017-2030)
11.3.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Patient (2017-2030)
11.4.2. Market Revenue and Forecast, by Component (2017-2030)
11.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Patient (2017-2030)
11.4.4.2. Market Revenue and Forecast, by Component (2017-2030)
11.4.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Patient (2017-2030)
11.4.5.2. Market Revenue and Forecast, by Component (2017-2030)
11.4.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Patient (2017-2030)
11.4.6.2. Market Revenue and Forecast, by Component (2017-2030)
11.4.6.3. Market Revenue and Forecast, by End-use (2017-2030)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Patient (2017-2030)
11.4.7.2. Market Revenue and Forecast, by Component (2017-2030)
11.4.7.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Patient (2017-2030)
11.5.2. Market Revenue and Forecast, by Component (2017-2030)
11.5.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Patient (2017-2030)
11.5.4.2. Market Revenue and Forecast, by Component (2017-2030)
11.5.4.3. Market Revenue and Forecast, by End-use (2017-2030)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Patient (2017-2030)
11.5.5.2. Market Revenue and Forecast, by Component (2017-2030)
11.5.5.3. Market Revenue and Forecast, by End-use (2017-2030)
Chapter 12. Company Profiles
12.1. Shimmer
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Empatica
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. SOC Telemed
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Eagle Telemedicine
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Sevaro
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Tele Specialists
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Chiron Health
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. RTTC
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Science Soft USA Corporation
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Vidyo, Inc.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers